

## A New Approach to Asymmetric Synthesis of Stork's Prostaglandin Intermediate


Makoto Nakazawa, Yasuharu Sakamoto, and Takashi Takahashi\*

Katsuhiko Tomooka, Katsuya Ishikawa, and Takeshi Nakai\*

Department of Chemical Technology, Tokyo Institute of Technology, Meguro-ku, Tokyo 152, JAPAN

**Summary :** A stereocontrolled approach to asymmetric synthesis of Stork's prostaglandin intermediate **3** has been developed which involves the [2,3]-Wittig rearrangement and the Pd(II)-catalyzed allylic acetate rearrangement as the key steps.


Among many synthetic intermediates for natural and unnatural prostaglandins,<sup>1)</sup> the Stork intermediate **3**<sup>2)</sup> is undoubtedly an ideal one. Recently, one of the author groups has reported two entries for **3**; one employs the three-component coupling process using vinylzincate **2**<sup>3,4)</sup> instead of the vinylcuprate and the other one is based on the intramolecular (3+2)-cycloaddition of nitrile oxide **4**.<sup>5)</sup> In these syntheses, the two stereogenic centers C<sub>11</sub>(R) and C<sub>15</sub>(S) are employed. Herein we disclose a new strategy (Scheme 1), wherein the C<sub>11</sub>(R) chirality in **5** derived from the commercially available cyclopentenone **1** is exploited to control the rest of chiralities in **3** via the [2,3]-Wittig rearrangement<sup>6)</sup> (**5**→**6**) and the Pd(II)-catalyzed allylic rearrangement<sup>7)</sup> (**6**→**7**).



(Scheme 1)


The key features of the present synthesis are two-fold. First, the [2,3]-Wittig rearrangement of **5** proceeds in a highly stereoselective fashion to establish the C<sub>12</sub>(*R*) and C<sub>13</sub>(*R*) configurations, together with the formation of the C<sub>8</sub>-exocyclic double bond in **6**. Second, the C<sub>13</sub>(*R*) chirality thus created is specifically transmitted to the desired C<sub>15</sub>(*S*) chirality in **7** by means of the Pd(II)-catalyzed rearrangement of the allylic acetate **6**. Thus, the overall transformation permits ready access to the desired configurations at C<sub>12</sub>, C<sub>13</sub> and C<sub>15</sub>, as well as the required exo-methylene at C<sub>8</sub>.

The propargylic ether **5b**, serving as a precursor to the prostaglandin skeleton, was prepared as outlined in Scheme 2. Reaction of (+)-enone **1** (>99% ee) with bromine (CCl<sub>4</sub>, 0 °C) followed by treatment of the resulting dibromide with triethylamine gave bromoenone **8** which was then reduced (NaBH<sub>4</sub>/CeCl<sub>3</sub>·7H<sub>2</sub>O<sup>8</sup>), MeOH, -20 °C) to afford a mixture of the 9 $\alpha$ - and 9 $\beta$ -alcohol **9** (9 $\alpha$  : 9 $\beta$  = 86 : 14) in 96% overall yield. Without separation of these isomers, **9** was converted to the allylic alcohol **10** in 75% overall yield via protection of the hydroxy group in **9** with ethyl vinyl ether and generation of the vinylic lithium (*n*-BuLi, THF, -78 °C) followed by addition of formaldehyde. Etherification of **10** with propargylic iodide **11** (KOH/*n*-Bu<sub>4</sub>NI, benzene, 0 °C; 92%) followed by removal of the ethoxyethyl group (PPTS, MeOH; 56%) gave, after separation of the C<sub>9</sub>-epimer, the 9 $\alpha$ -alcohol **5a**<sup>9</sup> which was treated with *t*-butyldimethylsilyl chloride (TBSCl) to give ether **5b** in 92% yield.




The [2,3]-Wittig rearrangement of **5b** was carried out with *t*-BuLi under the standard conditions (THF, -78 °C, 1h) to afford a mixture of the stereoisomers **12** and **13** (75 : 25) in 78% yield.<sup>10</sup> To improve the stereoselectivity in the [2,3]-Wittig process, we chose the trimethylsilyl(TMS) derivative **5c** as the substrate which was prepared from **10** in four steps<sup>11</sup>) (Scheme 3). The [2,3]-Wittig rearrangement of **5c** with *n*-BuLi was found to afford 90% yield of the single stereoisomer **14** which was then converted to the amyl derivative **12** as follows. Selective deprotection of the TMS group of **14** (AgNO<sub>3</sub>, EtOH; 83%) followed by protection of the hydroxy group with 2-methoxypropene gave alkyne **15**. Alkylation of **15** (*n*-BuLi, THF/HMPA, *n*-C<sub>5</sub>H<sub>11</sub>I, -20

°C) followed by deprotection of the acetal moiety (PPTS, MeOH, 0 °C) afforded the amyl derivative **12** in 89% yield.




Construction of the  $\omega$ -side chain from the [2,3]-Wittig product **12** was carried out via the Pd(II)-catalyzed 1,3-rearrangement<sup>12)</sup> of allylic acetate **6**. Acetate **6** was prepared in 78% yield from **12** by trans reduction of the triple bond (Red-Al<sup>®</sup>, 40 °C) followed by acetylation (Ac<sub>2</sub>O, Py). The Pd(II)-catalyzed rearrangement of **6** [PdCl<sub>2</sub>(MeCN)<sub>2</sub> (4 mol%), THF, reflux] gave rise to a 27 : 73 mixture<sup>13)</sup> of the allylic acetates **6** and **7**<sup>14)</sup> in 86% combined yield. In this rearrangement, neither the C13(*Z*)-nor the C15(*R*)-isomers was detected. Conversion of **7** to Stork's intermediate **3** (R=TBS) required two operations; (1) reprotection of the allylic acetate to the TBS group and (2) selective oxidation of the 9-hydroxyl to carbonyl group. Thus, hydrolysis of the acetate group of **7** (K<sub>2</sub>CO<sub>3</sub>, MeOH) followed by protection of the resulting alcohol (TBSCl, imidazole) gave the tri-TBS derivative **16** in 80% overall yield. Acid treatment of **16** (80% aq. AcOH, r.t.) produced a mixture of the di-TBS derivatives (C<sub>11,15</sub>-di-TBS : C<sub>9,11</sub>-di-TBS = 2 : 1). The desired 9-hydroxy derivative was isolated and oxidized (MnO<sub>2</sub>, *n*-hexane) to furnish the desired enone **3** in 75% yield. The spectral data (NMR, IR) of **3** are identical with the literature values.<sup>2g)</sup> Further improvement of the present approach is in progress.



**Acknowledgment.** We are grateful to Sumitomo Chemical Co. and Teijin Co. for providing the optically active enone **1**.

#### References and Notes:

- 1) a) Bindra, J. S.; Bindra, R. *Prostaglandin Synthesis*; Academic Press: New York, 1977. b) Mitra, A. *Synthesis of Prostaglandin*; Wiley-Interscience: New York, 1977.
- 2) a) Stork, G.; Isobe, M. *J. Am. Chem. Soc.* **1975**, *97*, 4745. b) Stork, G.; Isobe, M. *J. Am. Chem. Soc.* **1975**, *97*, 6260. c) Stork, G.; Kraus, G. *J. Am. Chem. Soc.* **1976**, *98*, 6747. d) Kondo, K.; Umemoto, T.; Yako, K.; Tunemoto, D. *Tetrahedron Lett.* **1978**, *41*, 3927. e) Shwartz, J.; Loots, M. J.; Kosugi, H. *J. Am. Chem. Soc.* **1980**, *102*, 1333. f) Kozikowski, A. P.; Stein, P. D. *J. Org. Chem.* **1984**, *49*, 2301. g) Okamoto, S.; Kobayashi, Y.; Kato, H.; Hori, K.; Takahashi, T.; Tsuji, J.; Sato, F. *J. Org. Chem.* **1988**, *53*, 5590.
- 3) Takahashi, T.; Nakazawa, M.; Takatori, K.; Nishimura, S.; Yamamoto K. *Natural Product Lett.* (1993) in press.
- 4) PGs syntheses by using vinylzincates; a) Morita, Y.; Suzuki, M.; Noyori, R. *J. Org. Chem. Soc.* **1989**, *54*, 1785. b) Takahashi, T.; Nakazawa, M.; Kanoh, M.; Yamamoto. K. *Tetrahedron Lett.* **1990**, *31*, 7349.
- 5) Takahashi, T.; Shimayama, T.; Miyazawa, M.; Nakazawa, M.; Yamada, H.; Takatori, K.; Kajiwara, M. *Tetrahedron Lett.* **1992**, *33*, 5973.
- 6) Review: Nakai, T.; Mikami, K. *Chem. Rev.* **1986**, *86*, 885.
- 7) Review: Overman, L. E. *Angew. Chem., Int. Ed. Engl.* **1984**, *23*, 579. See also ref. 12).
- 8) Luche, J. -L. *J. Am. Chem. Soc.* **1978**, *100*, 2226.
- 9) The absolute stereochemistry at C9 in **5a** was determined by the CD spectrum of the p-bromobenzoate derivative;  $[\Theta] = -5.04 \times 10^4$  ( $7.88 \times 10^{-5}$  mol/L, 243 nm, EtOH; UV 246 nm).
- 10) The relative stereochemistry over C11, C12 and C13 in the major product **12** was determined by the following way. The individual oxidation of **12** and **13** with  $\text{MnO}_2$  gave the same ketone **A**. This result indicates that the [2,3]-Wittig rearrangement gave the single stereochemistry at C12 but diastereomers at C13. The absolute stereochemistry at C13 in **12** was determined by the CD spectrum of the allylic benzoate **B**;  $[\Theta] = -6.66 \times 10^3$  ( $1.65 \times 10^{-4}$  mol/L, 243 nm, EtOH; UV 244 nm).



- 11) 1) NaH, propargyl bromide, HMPA, 87%; 2) EtMgBr, TMSCl; 3) PPTS, MeOH, 41%; 4) TBSCl, imidazole, 90%.
- 12) a) Grieco, P. A.; Takigawa, T.; Bongers, S. L.; Tanaka, H. *J. Am. Chem. Soc.* **1980**, *102*, 7587. b) Danishefsky, S. J.; Cabel, M. P.; Chow, K. *J. Am. Chem. Soc.* **1989**, *111*, 3456.
- 13) Based on the assumption of a thermodynamically controlled process for the Pd(II)-catalyzed allylic acetate rearrangement, MM2 calculations on MACROMODEL (ver. 2.5) considering a Boltzman distribution at 67°C suggest that allylic acetates **6** and **7** would exist in a ratio 20 : 80. We are grateful to Professor Clark Still for providing a copy of MACROMODEL (ver. 2.5).
- 14) The absolute stereochemistry at C15 in the product **7** was determined by the CD spectrum of the p-bromobenzoate derivative;  $[\Theta] = 1.78 \times 10^5$  ( $4.78 \times 10^{-5}$  mol/L, 244 nm, EtOH; UV 244 nm).

(Received in Japan 24 April 1993)